Case Western Reserve University, Cleveland, Ohio, USA.
Br J Haematol. 2022 Jul;198(2):225-226. doi: 10.1111/bjh.18215. Epub 2022 Apr 26.
Immunosuppression with rituximab in immune-mediated thrombotic thrombocytopenic purpura helps decrease production of autoantibody mediating ADAMTS13 clearance from circulation. Failure to respond to rituximab in a satisfactory way or made difficult by adverse events to the medication does not represent a reason to stop considering anti-CD20 therapies to control antibody production. Therefore, both of atumumab and obinutuzumab with specificity to CD20, represent potentially valuable therapeutic tools in patients who are not candidates for rituximab. Commentary on: Doyle et al. The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura. Br J Haematol. 2022;198:391-396..
免疫抑制治疗联合利妥昔单抗治疗免疫性血栓性血小板减少性紫癜有助于减少介导 ADAMTS13 从循环中清除的自身抗体的产生。对利妥昔单抗治疗反应不佳或因药物不良反应而使治疗变得困难，并不能成为停止考虑抗 CD20 治疗以控制抗体产生的理由。因此，针对 CD20 的奥妥珠单抗和奥法妥珠单抗都代表了一种潜在有价值的治疗工具，可用于那些不适合利妥昔单抗治疗的患者。述评：Doyle 等人。奥妥珠单抗和奥法妥珠单抗在治疗免疫性血栓性血小板减少性紫癜中的应用。《英国血液学杂志》2022;198:391-396。
